Abstract:All- trans -retinoic acid (ATRA)-based differentiation therapy of acute promyelocytic leukemia (APL) represents one of the most clinically effective examples of precision medicine and the first example of targeted oncoprotein degradation. The success of ATRA in APL, however, remains to be translated to non-APL acute myeloid leukemia (AML). We previously showed that aberrant histone modifications, including histone H3 lysine 4 (H3K4) and lysine 27 (H3K27) methylation, were associated with this lack of response and that epigenetic therapy with small molecule inhibitors of the H3K4 demethylase LSD1/KDM1A could reprogram AML cells to respond to ATRA. Serving as the enzymatic component of Polycomb Repressive Complex 2, EZH2/KMT6A methyltransferase plays a critical role in normal hematopoiesis by affecting the balance between self-renewal and differentiation. The canonical function of EZH2 is methylation of H3K27, although important non-canonical roles have recently been described. EZH2 mutation or deregulated expression has been conclusively demonstrated in the pathogenesis of AML and response to treatment, thus making it an attractive therapeutic target. In this study, we therefore investigated whether inhibition of EZH2 might also improve the response of non-APL AML cells to ATRA-based therapy. We focused on GSK-343, a pyridone-containing S-adenosyl-L-methionine cofactor-competitive EZH2 inhibitor that is representative of its class, and HKMTI-1-005, a substrate-competitive dual inhibitor targeting EZH2 and the closely related G9A/GLP H3K9 methyltransferases. We found that treatment with HKMTI-1-005 phenocopied EZH2 knockdown and was more effective in inducing differentiation than GSK-343, despite the efficacy of GSK-343 in terms of abolishing H3K27 trimethylation. Furthermore, transcriptomic analysis revealed that in contrast to treatment with GSK-343, HKMTI-1-005 upregulated the expression of differentiation pathway genes with and without ATRA, while downregulating genes associated with a hematopoietic stem cell phenotype. These results pointed to a non-canonical role for EZH2, which was supported by the finding that EZH2 associates with the master regulator of myeloid differentiation, RARα, in an ATRA-dependent manner that was enhanced by HKMTI-1-005, possibly playing a role in co-regulator complex exchange during transcriptional activation. In summary, our results strongly suggest that addition of HKMTI-1-005 to ATRA is a new therapeutic approach against AML that warrants further investigation.

Involvement of Mitogen-Activated Protein Kinase in Signal Transducer and Activator of Transcription-1 Mediated Differentiation Induced by Bortezomib in Acute Myeloid Leukemia Cells

Data from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia

Supplementary Figure 1 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.

Bortezomib Induces Cell Apoptosis and Increases the Efficacy of Α PD-1 in BCR::ABL T315I Mutation CML by Targeting UBE2Q1

Wnt Signaling is Involved in 6-Benzylthioinosine-induced AML Cell Differentiation

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes

Bortezomib Induces Cell Apoptosis and Increases the Efficacy of Αpd-1 in BCR::ABL T315I Mutation CML by Targeting UBE2Q1.

The Proteasome Inhibitor Bortezomib Enhances Atra-Induced Differentiation Of Neuroblastoma Cells Via The Jnk Mitogen-Activated Protein Kinase Pathway

Supplementary Figure 3 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Supplementary Figure 2 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

The Selective Activator Protein-1 Inhibitor T-5224 Regulates the IRF4/MYC Axis and Exerts Cooperative Antimyeloma Activity with Bortezomib

Bortezomib suppresses acute myelogenous leukaemia stem‐like KG‐1a cells via NF‐κB inhibition and the induction of oxidative stress

Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger miR-135a-5p- Dependent Apoptosis

Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells

Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia

Phorbol Ester-Induced Mononuclear Cell Differentiation Is Blocked By The Mitogen-Activated Protein Kinase Kinase (Mek) Inhibitor Pd98059

Bortezomib Interferes with C-Kit Processing and Transforms the T(8;21)-Generated Fusion Proteins into Tumor-Suppressing Fragments in Leukemia Cells